Sarepta Therapeutics, Inc. to Post Q4 2025 Earnings of $2.68 Per Share, William Blair Forecasts (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities researchers at William Blair raised their Q4 2025 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Thursday, August 8th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of $2.68 for the quarter, up from their prior estimate of $2.63. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $3.76 per share.

SRPT has been the subject of several other reports. Cantor Fitzgerald reduced their price objective on Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating for the company in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $235.00 price target on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and dropped their price objective for the stock from $185.00 to $179.00 in a report on Thursday. Oppenheimer raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research report on Tuesday, May 14th. Finally, Morgan Stanley reissued an “overweight” rating and set a $165.00 target price on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $186.22.

Sarepta Therapeutics Stock Performance

SRPT traded down $6.34 during midday trading on Friday, reaching $130.06. The company’s stock had a trading volume of 472,840 shares, compared to its average volume of 1,377,733. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. The company has a fifty day simple moving average of $141.00 and a 200 day simple moving average of $131.41. The stock has a market cap of $12.29 billion, a P/E ratio of 1,240.00 and a beta of 0.89. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the business posted ($0.27) earnings per share. The firm’s revenue was up 38.9% compared to the same quarter last year.

Insider Activity

In related news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares in the company, valued at approximately $2,768,217.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Capital International Investors grew its holdings in Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after acquiring an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Norges Bank bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $80,697,000. Bank of Nova Scotia acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $50,990,000. Finally, Avoro Capital Advisors LLC raised its position in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after purchasing an additional 319,444 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.